Pharmaceutical Technology

JUNE 12, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Clinical Trials 130

Clinical Trials Clinical Trials Manufacturing Marketing 130

Rethinking Clinical Trials

JUNE 12, 2025

A new chapter of the Living Textbook of Pragmatic Clinical Trials describes regulatory requirements for informed consent, waivers and alterations of consent, mechanisms for notification, and research participants’ perspectives on a variety of approaches to consent and notification—all with a focus on special considerations for pragmatic clinical trials.

Trials 100

Trials Clinical Trials Clinical Trials Regulation 100

Pharmaceutical Technology

JUNE 12, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Clinical Trials 130

Clinical Trials Clinical Trials Trials Manufacturing 130

Scienmag

JUNE 12, 2025

For decades, the exploration of the human brain through noninvasive techniques has been a frontier of neuroscience, with researchers pursuing the unseen depths of this complex organ. The traditional method utilized in this quest is known as functional near-infrared spectroscopy, or fNIRS. This optical imaging approach has offered a window into brain activity by measuring how light is absorbed by blood flowing through the brain, allowing scientists to infer areas of activity and engagement.

Scientist 59

Scientist Research Engineer Development 59

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.

Compliance

The Pharma Data

JUNE 12, 2025

Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and promising Phase 1b data demonstrating strong antileukemic activity and a favorable safety profile for bleximenib (JNJ-75276617) in combination with venetoclax (VEN) and azacitidine (AZA) in patients with acute myeloid leukemia (AML) who harbor KMT2A gene rearrangements (KMT2Ar) or NPM1 mutations (NPM1

Gene 40

Gene Trials Clinical Development Development 40

Scienmag

JUNE 12, 2025

image: TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the prostate cancer premetastatic niche in bone. view more Credit: TTUHSC The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths.

Research 59

Research Protein Medicine Engineer 59

Scienmag

JUNE 12, 2025

image: Virginia Tech cancer researcher Jennifer Munson’s bioengineered stromal cells — which include fibroblastic reticular (left) and endothelial cells (right) — are the framework within a lymph node that provide structure, guide immune cell movement, and can influence the immune response. view more Credit: Jennifer Munson/Virginia Tech Scientists with the Fralin Biomedical Research Institute at VTC have created an engineered model of the supportive tissue found within a lymph node to study

Medicine 87

Medicine Research Engineer Immune Response 87

The Pharma Data

JUNE 12, 2025

EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib , a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers in patients with IgG4-related disease (IgG4-RD) , according to new data presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain (June 11–14).

Clinical Development 40

Clinical Development Medicine Development Drugs 40

Scienmag

JUNE 12, 2025

image: Solvents play a critical role in boosting drug-loading capacity of MOFs. view more Credit: Osaka Metropolitan University Even the best products won’t meet expectations if they are packed poorly — packaging matters. The same goes for drug delivery. Osaka Metropolitan University researchers have uncovered the critical role played by solvents in how effectively drugs can be loaded into metal–organic frameworks (MOFs), a promising class of drug carriers.

Drug Delivery 64

Drug Delivery Drugs Drug Delivery Systems Packaging 64

The Pharma Data

JUNE 12, 2025

Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel, Fc-free, anti-CD40 Ligand (anti-CD40L) biologic candidate for the treatment of Systemic Lupus Erythematosus (SLE).

Trials 40

Trials Clinical Development Clinical Research Regulation 40

Advertisement

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

Trials

Scienmag

JUNE 12, 2025

Zachary Sexton and colleagues have developed a design platform that can rapidly generate vasculature trees that can then be bioprinted and used to successfully perfuse living tissue constructs. The platform improves the design and production of complex vascular networks that will be needed for manufacturing human tissues and organs in the future. As the researchers note, the manufacture of tissues with multiple cell types has improved recently.

Manufacturing 98

Manufacturing Engineer Packaging Packaging 98

Pharmaceutical Technology

JUNE 12, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Clinical Trials 130

Clinical Trials Clinical Trials Manufacturing Marketing 130

Scienmag

JUNE 12, 2025

The article summarizes results of research and possible future clinical applications of the microbiome and provides instructions for doctors. More communication is needed between basic and clinical research to accelerate the arrival of this valuable tool at the patient's bedside. There are many possible diagnostic and therapeutic applications: from the fight against antibiotic resistance to colon cancer screening, predicting response to immunotherapy and enhancing its effectiveness in the fight

Research 59

Research Doctor Doctors Bacteria 59

STAT News

JUNE 12, 2025

When House Republicans voted in the wee hours of the morning of May 22 to cut approximately $700 billion from Medicaid , they moved one step closer to rendering dangerously vulnerable the millions of Medicaid recipients struggling with mental illness and substance use disorder. Medicaid, which covers more than 72 million Americans, is the single largest payer of behavioral health services , which includes mental health and substance use disorder treatment.

142

142

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

Compliance

Scienmag

JUNE 12, 2025

image: New research from the University of Virginia School of Medicine’s Marina Weiler, PhD, and colleagues suggests that out-of-body experiences may be a coping mechanism in response to trauma or overwhelming stress. view more Credit: UVA Health Out-of-body experiences – where people feel like spirits disconnected from their physical form – may be a coping mechanism triggered by trauma or other overwhelming stress, new University of Virginia School of Medicine research suggests.

Research 59

Research Medicine Scientist 59

Pharmaceutical Technology

JUNE 12, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Gene Therapy 130

Gene Therapy Gene Development Clinical Trials 130

Scienmag

JUNE 12, 2025

image: Strontium optical lattice clock at NPL view more Credit: Andrew Brookes WASHINGTON — In a new study, researchers carried out the most extensive coordinated comparison of optical clocks to date by operating clocks and the links connecting them simultaneously across six countries. Spanning thousands of kilometers, the experiment represents a significant step toward redefining the second and ultimately establishing a global optical time scale.

Research 78

Research Scientist Engineer 78

PharmTech

JUNE 12, 2025

News All News Bio/Pharma News Publications All Publications PharmTech PharmTech Europe Resources Marketplace ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management Peer-Reviewed Research PharmTech Products Pharma Insights Sponsored Podcasts Sponsored Videos Sponsored eBooks Whitepapers Webcasts Multimedia All Videos Ask the Expert Behind The Headlines Buy, Sell, Hold Drug Digest Videos Drug Solutions Podcast Peer Exchange Sexy Science Tech Talk Conference Conference Coverage Confer

Manufacturing 59

Manufacturing Cosmetics Production Drugs 59

Advertisement

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

Life Science

Scienmag

JUNE 12, 2025

image: The heterogeneity of iCCA poses significant challenges to both targeted therapy and immunotherapy, necessitating in-depth exploration at the molecular and subtyping levels. Investigating genetic variations, signaling pathway alterations, and molecular subtypes can aid in patient stratification. Stratifying iCCA patients allows for more precise treatment selection, ultimately improving survival outcomes.

Genetics 59

Genetics Gene Expression Research Gene 59

pharmaphorum

JUNE 12, 2025

Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.

Production 76

Production FDA Approval 76

NPR Health - Shots

JUNE 12, 2025

Laid off workers were told their notices of an upcoming reduction in force were "revoked." Officials didn't explain why HHS appeared to be restoring hundreds of jobs it previously called duplicative.

123

123

The Pharma Data

JUNE 12, 2025

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing its Shigella vaccine candidate, altSonflex1-2-3 , to Bharat Biotech International Limited (BBIL). This strategic collaboration aims to enable the continued clinical development and eventual delivery of a low-cost, effective Shigella vaccine to chi

Licensing 40

Licensing Licensing Vaccination Vaccine 40

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Pharmaceutical Technology

JUNE 12, 2025

The FDA has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat Parkinson’s disease (PD).

Gene Therapy 130

Gene Therapy FDA Approval Gene Drugs 130

Pharma Times

JUNE 12, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Levicept presents new LEVI-04 data at EULAR by John Pinching | 12th Jun 2025 | News Biotech firm shares phase 2 findings on novel osteoarthritis treatmen Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025).

Marketing 117

Marketing Engineer Branding Protein 117

STAT News

JUNE 12, 2025

On the surface, the National Institutes of Health’s brand new autism research initiative is alluring: $50 million to study autism’s causes and services for autistic people, and access to data from existing public and private databases.  But the opportunity’s nontraditional funding mechanism, accelerated timeline, and lack of transparency around who will review the applications are casting a shadow over the initiative, which many scientists and potential applicants worry

Research 114

Research Branding Scientist 114

Drug Discovery World podcast

JUNE 12, 2025

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “ Advances in neuroscience drug discovery ”, “ Putting human data at the centre of drug discovery ”, and “ The era of precision neuroscience ”.

Drugs 52

Drugs Medicine Development 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharmaceutical Commerce

JUNE 12, 2025

News News Pharma Pulse Academy Publications Partner Perspectives Webcasts Resources Conferences Conference Coverage Conference Listing Events Videos Videos Peer Exchange Podcasts Editorial Podcasts Sponsored Podcasts Subscribe Choose Specialty Brand & Product Security Brand & Product Security Brand & Product Security Brand & Product Security Business and Finance Cold Chain Cold Chain Cold Chain Cold Chain Commercial Channels Data & Technology Data & Technology Data &

Life Science 52

Life Science Branding Marketing Production 52

The Pharma Data

JUNE 12, 2025

Novartis’ Fabhalta Shows Meaningful Hemoglobin Improvement in PNH Patients, Reinforcing Benefit of Oral Monotherapy Novartis recently announced positive results from its APPULSE-PNH study — a Phase IIIB trial evaluating Fabhalta® (iptacopan) in adult patients with paroxysomal nocturnal hemoglobinuria (PNH) who have a baseline hemoglobin (Hb) level of 10 g/dL or greater and have previously been treated with standard C5 inhibitor therapy (eculizumab or ravulizumab).

Doctor 40

Doctor Doctors Gene Research 40

Pharmaceutical Technology

JUNE 12, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Research 147

Research Drugs Clinical Trials Clinical Trials 147

STAT News

JUNE 12, 2025

As an adoptee who was placed in foster care at 18 months old, I’ve never known my full racial heritage, family tree, or medical history. People have often suggested I try 23andMe or a similar company to get more information on my genetics. But I’ve always felt uneasy about it. So, I felt a little vindicated when I saw the news that Regeneron Pharmaceuticals is set to acquire 23andMe , including its troves of customer data, for $256 million.

Genetics 124

Genetics 124

Advertisement

Clinical Supply